The telehealth-consultation platform posted an increase in profit and revenue for the second quarter on growth in subscribers ...

CNBC's Brandon Gomez reports on Hims & Hers Health's latest earnings report. Trump administration announces major tourist ...

Hims & Hers Health, a telehealth platform that sells knock offs of popular weight loss drugs, sank in after-hours trading ...

Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported ...

Hims & Hers Health's Q2 revenue miss and decelerating growth triggered a stock drop. Find out why I maintain a 'Buy' rating ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Key Points Revenue (GAAP) climbed 73% year over year in the second quarter of 2025 but missed consensus estimates by 1.2%. Net income (GAAP) and Adjusted EBITDA more than doubled, while gross margin ...

In June, Novo Nordisk ( NVO) ended a brief partnership that allowed Hims & Hers members to access its weight loss drug, Wegovy. The termination was due to concerns that the company was violating ...

Shares of Hims & Hers Inc. fell after hours on Monday after the wellness and telehealth platform’s third-quarter forecast ...

Online telehealth company Hims and Hers Health missed Wall Street estimates for second-quarter revenue on Monday, as it lost subscribers for compounded versions of weight-loss drugs, sending its ...

Hims and Hers Health missed Wall Street estimates for second-quarter revenue on Monday, hit by weakness in its wholesale business, sending its shares down 9% in extended trading.